TEE
LOGC

Tibra Equities Europe’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Tibra Equities Europe’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-76,500
Closed -$340K – 241
2021
Q2 		$340K Buy
+76,500
New +$389K 0.11% 85

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Tibra Equities Europe's LOGC Position: Q3 2021 in Review

Tibra Equities Europe sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2021, closing a stake of 76,500 shares — an estimated $340K sold.

Tibra Equities Europe first reported a position in LOGC in Q2 2021 and held it in 1 quarter. The position peaked at $340K in Q2 2021. 57 funds tracked by Wall St. Rank hold LOGC as of Q3 2021.

  • Tibra Equities Europe reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 76,500 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $340K.
  • Tibra Equities Europe first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's LogicBio Therapeutics, Inc. Common Stock position peaked at $340K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.